Matinas BioPharma Holdings, Inc. (MTNB)
NYSEAMERICAN: MTNB · IEX Real-Time Price · USD
0.157
-0.004 (-2.18%)
Jul 2, 2024, 4:00 PM EDT - Market closed

MTNB Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 2013
Revenue
1.13.190.0300
Upgrade
Revenue Growth (YoY)
-65.62%9560.61%---
Upgrade
Gross Profit
1.13.190.0300
Upgrade
Selling, General & Admin
10.3711.110.1910.017.78
Upgrade
Research & Development
14.4916.6814.5814.3611.23
Upgrade
Operating Expenses
24.8627.7824.7724.3619.01
Upgrade
Operating Income
-23.77-24.59-24.74-24.36-19.01
Upgrade
Other Expense / Income
-0.82-3.59-1.45-1.92-1.64
Upgrade
Pretax Income
-22.94-21-23.28-22.45-17.37
Upgrade
Net Income
-22.94-21-23.28-22.45-17.37
Upgrade
Preferred Dividends
000.40.790.92
Upgrade
Net Income Common
-22.94-21-23.68-23.24-18.3
Upgrade
Shares Outstanding (Basic)
217217210197145
Upgrade
Shares Outstanding (Diluted)
217217210197145
Upgrade
Shares Change
0.21%3.16%6.75%35.61%48.00%
Upgrade
EPS (Basic)
-0.11-0.10-0.11-0.12-0.13
Upgrade
EPS (Diluted)
-0.11-0.10-0.11-0.12-0.13
Upgrade
Free Cash Flow
-15.5-20.05-15.48-17.37-14.5
Upgrade
Free Cash Flow Per Share
-0.07-0.09-0.07-0.09-0.10
Upgrade
Gross Margin
100.00%100.00%100.00%--
Upgrade
Operating Margin
-2168.43%-771.33%-74954.55%--
Upgrade
Profit Margin
-2093.25%-658.63%-71754.55%--
Upgrade
Free Cash Flow Margin
-1413.87%-628.86%-46918.18%--
Upgrade
EBITDA
-22-20.1-22.5-21.67-16.59
Upgrade
EBITDA Margin
-2007.39%-630.46%-68187.88%--
Upgrade
Depreciation & Amortization
0.940.90.780.770.78
Upgrade
EBIT
-22.94-21-23.28-22.45-17.37
Upgrade
EBIT Margin
-2093.25%-658.63%-70554.55%--
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).